Manually validating large datasets is slow, labor-intensive, and can’t keep up with deadlines, making anomaly detection and reporting overly complex.
AI-Enhanced Transparency Reporting minimizes manual effort by automating data cleansing, validation, standardization, and organization, ensuring cleaner, compliant, and submission-ready spend reports.
With AI-trained models, compliance teams gain more time, less friction, and greater confidence in the accuracy and integrity of their federal and state level reports.
Submission: 31st March
Publication: 30th June
Department of Health and Human Services
Centers for Medicare and Medicaid Services
Applicable Pharmaceutical, Medical device manufacturers, and Group purchase organizations (GPO)
All payments, gifts and other transfers of value made to U.S. physicians and teaching hospitals:
All Applicable Pharmaceutical, medical device manufacturers and group purchase organizations (GPO) that fill the following criteria:
OR
Annual reports must be submitted to the Centers for Medicare and Medicaid Services through the online portal.
Submission: 1st March
Nevada Board of Pharmacy
Pharmaceutical manufacturers
Pharmaceutical manufacturer sales representatives
A list of HCPs to who have been provided by a pharmaceutical sales representative:
Data points to be disclosed:
If a sample drug was provided, the following fields are also required:
Pharmaceutical Manufacturer means a person who:
Pharmaceutical sales representative means a person who markets prescription drugs to providers of health care licensed, certified or registered in this State, pharmacies or employees thereof, operators or employees of medical facilities or persons licensed or certified under the provisions of title 57 of NRS.
Note: Reporting for Pharmaceutical Representatives, is both the individual’s responsibility as well as the manufacturer’s.
Submission: 1st May
Minnesota Board of Pharmacy
Pharmaceutical manufacturers
Payments, reimbursement or other compensation paid to HCPs registered and practicing in Minnesota during the calendar year in which the transfer of value is $100 or more, to a particular covered recipient.
Data points to be disclosed:
Any entity engaged in manufacturing, wholesale distribution, or selling of drugs and/or medical device, medicines, chemicals, or poisons for medicinal purposes other than to the consuming public or patient, licensed by the state.
Reports must be filed in an electronic format. Applicable manufacturers are required to fill out the spreadsheet available on Minnesota Board of Pharmacy website and return it to the Board either attached to an e-mail ([email protected]) or copied onto a CD-ROM.
Submission: 1st July
D.C. Department of Health
Pharmaceuticals – Manufacturers and labelers
The required data to be disclosed will vary depending on whether the expense is attributable to gifts, advertising or aggregate cost.
Reports must be submitted by July 1, and the signed statement along with the check must be received no later than 7 days after the report’s submission.
Submission: 1st April
Oregon Department of Consumer and Business Services
Pharmaceutical Company Representatives
An individual authorized, certified, and licensed under the laws of Oregon to prescribe, dispense or provide pharmaceutical products, i.e., drugs, to patients for treatment, diagnosis, injury, congenital or disease prevention is a covered recipient.
The interactions that healthcare professionals (HCPs) have with pharmaceutical representatives include but are not limited to video conference, email exchange, telephonic conversation, meeting in person, leveraging other communication channels, or leaving material, i.e., drugs samples for the specific HPC without communicating personally is termed as reported.
Data to be disclosed:
Pharmaceutical Company Representatives
Exemption
No Exemptions.
A disclosure log can be prepared and maintained by license holders/representatives. This log should contain all pharmaceutical representatives’ interactions with healthcare providers. This disclosure log must be turned into a program via the iReg Portal before April 1st, 2023.
The reporting spreadsheet is available on this web page. A registration email, with instructions, for the iReg portal is sent to the license holder once a license application is approved.
Important Links:
https://dfr.oregon.gov/business/licensing/pharmaceutical-rep/pages/pharmaceutical-rep.aspx
Submission: 1st July
Massachusetts Department of Public Health
Applicable Pharmaceuticals and medical device manufacturers
Companies do not have to report transfers of value made to:
Note: If there are no reportable transactions, email to [email protected] stating “Company has no reportable spend transactions to report for the 20XX calendar year.”
Submission: 1st July
Connecticut State Department of Consumer Protection
Commissioner of Public Health
Pharmaceutical and medical device manufacturers
Companies do not have to report transfers of value made to:
Note: If there are no reportable transactions, email to [email protected] stating “Company has no reportable spend transactions to report for the 20XX calendar year.”
Registration Due Date: 1st Jan
Report Due Date: 1st April
Vermont Attorney General’s Office
Pharmaceutical and medical device manufacturers
Data points to be disclosed:
“Manufacturer” means a pharmaceutical, biological product, or medical device manufacturer or any other person who is engaged in the production, preparation, propagation, compounding, processing, marketing, packaging, repacking, distributing, or labeling of prescribed products.
Submission: 1st April
U.S. Food and Drug Administration
Applicable Pharmaceutical manufacturers
Healthcare Professionals
According to the section 6004 of the ACA, manufacturers and authorized distributors of applicable drugs must submit the identity and quantity of drug samples requested and the identity and quantity of drug samples distributed, aggregated by the name, address, professional designation, signature of the practitioner who made request, and signature of the practitioner or someone designated by the practitioner for receiving the distributed drug samples.
Data points to be disclosed:
“[T]he person who performs all of the following operations that are required to produce the product: (1) Mixing, (2) granulating, (3) milling, (4) molding, (5) lyophilizing, (6) tableting, (7) encapsulating, (8) coating, (9) sterilizing, and (10) filling sterile, aerosol, or gaseous drugs into dispensing containers.”
“[T]hose distributors with whom a manufacturer has established an ongoing relationship to distribute such manufacturer’s products.”
Note: An entity that is an ADR under section 503(d) of the FD&C Act is also an ADR under section 1128H of the SSA.
When a manufacturer and ADR both have records regarding the same drug sample request or distribution, only one of the two entities should submit the required drug sample information to FDA.
Your usage of this site constitutes acceptance of our Terms of Use & Data Policy. The material on this say may not be reproduced, distributed, transmitted, cached, or otherwise used without qordata’s consent. qordata is an Equal Opportunity Employer. All qualified individuals are accepted as employees and will receive consideration for employment without regard to race, gender, color, age, religion, sex, national origin, protected veteran status, or any other characteristic protected under federal, state, or local law.
© qordata 0. All rights reserved | Sitemap | Privacy Policy | Terms of Use